{"success":true,"data":{"pressRelease":{"id":"171947","rtpr_id":"nACSKK5qDa-20261018","ticker":"UNCY","exchange":"NASDAQ","all_tickers":["UNCY"],"title":"UNCY ALERT: Securities Fraud Class Action Launched Against Unicycive Therapeutics, Inc. – November 2, 2026 Deadline","author":"ACCESSWIRE","published_at":"2026-10-18T16:20:00.315Z","article_body":"NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / October 18,\n2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit\nhas been filed on behalf of investors who purchased or otherwise acquired\nUnicycive Therapeutics, Inc. (NASDAQ:UNCY) securities.\n\nIf you suffered a loss on your Unicycive Therapeutics, Inc. investment and\nwould like to explore a potential recovery under the federal securities laws,\nLearn about Unicycive Therapeutics, Inc. Class Action (https://pr.report/sgb2)\nor contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call\n(212)363-7500 to speak to our team of experienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against Unicycive\nTherapeutics, Inc. that seeks to recover losses of shareholders who were\nadversely affected by alleged securities fraud between December 29, 2025 and\nJune 29, 2026.\n\nCASE DETAILS: The filed complaint alleges that defendants made false\nstatements and/or concealed that: (1) the Company had not inspected its\nthird-party manufacturing vendor's facility or otherwise audited the\nfacility's compliance with current good manufacturing practices; (2) as a\nresult, the Company lacked a reasonable basis to believe that the vendor had\nresolved the FDA's cited deficiencies; (3) there was an undisclosed risk that\nthe FDA would require additional information about the vendor's facility's\nmanufacturing practices; (4) as a result of the foregoing, the regulatory\napproval of OLC was reasonably likely to be delayed; and (5) that, as a result\nof the foregoing, defendants' positive statements about the Company's\nbusiness, operations, and prospects were materially misleading and/or lacked a\nreasonable basis.\n\nWHAT'S NEXT? If you purchased Unicycive Therapeutics, Inc. stock during the\nrelevant time frame - even if you still hold your shares, learn about your\nrights to seek a recovery (https://pr.report/sgb3). There is no cost or\nobligation to participate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/uncy-alert-securities-fraud-class-action-launched-against-unicyc-1238137)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSKK5qDa-20261018","title":"UNCY ALERT: Securities Fraud Class Action Launched Against Unicycive Therapeutics, Inc. – November 2, 2026 Deadline","author":"ACCESSWIRE","ticker":"UNCY","created":"2026-10-18T16:20:00.315Z","tickers":["UNCY"],"exchange":"NASDAQ","article_body":"NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / October 18,\n2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit\nhas been filed on behalf of investors who purchased or otherwise acquired\nUnicycive Therapeutics, Inc. (NASDAQ:UNCY) securities.\n\nIf you suffered a loss on your Unicycive Therapeutics, Inc. investment and\nwould like to explore a potential recovery under the federal securities laws,\nLearn about Unicycive Therapeutics, Inc. Class Action (https://pr.report/sgb2)\nor contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call\n(212)363-7500 to speak to our team of experienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against Unicycive\nTherapeutics, Inc. that seeks to recover losses of shareholders who were\nadversely affected by alleged securities fraud between December 29, 2025 and\nJune 29, 2026.\n\nCASE DETAILS: The filed complaint alleges that defendants made false\nstatements and/or concealed that: (1) the Company had not inspected its\nthird-party manufacturing vendor's facility or otherwise audited the\nfacility's compliance with current good manufacturing practices; (2) as a\nresult, the Company lacked a reasonable basis to believe that the vendor had\nresolved the FDA's cited deficiencies; (3) there was an undisclosed risk that\nthe FDA would require additional information about the vendor's facility's\nmanufacturing practices; (4) as a result of the foregoing, the regulatory\napproval of OLC was reasonably likely to be delayed; and (5) that, as a result\nof the foregoing, defendants' positive statements about the Company's\nbusiness, operations, and prospects were materially misleading and/or lacked a\nreasonable basis.\n\nWHAT'S NEXT? If you purchased Unicycive Therapeutics, Inc. stock during the\nrelevant time frame - even if you still hold your shares, learn about your\nrights to seek a recovery (https://pr.report/sgb3). There is no cost or\nobligation to participate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/uncy-alert-securities-fraud-class-action-launched-against-unicyc-1238137)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-18T16:20:00.364069838Z","server_sent_at_ms":1792340400364},"received_at":"2026-10-18T16:20:00.422Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/uncy-alert-securities-fraud-class-action-launched-against-unicyc-1238137"},"analysis":{"id":"160095","press_release_id":"171947","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["alleged unresolved FDA cGMP deficiencies at third-party manufacturing vendor","claims suggest OLC regulatory approval delay risk","class period December 29, 2025 - June 29, 2026; lead plaintiff deadline November 2, 2026"],"eventType":"legal_litigation","narrative":"Levi & Korsinsky announced a securities fraud class action filed against Unicycive Therapeutics covering investors who purchased UNCY securities between December 29, 2025 and June 29, 2026.\n\nThe complaint alleges the company misled investors about its third-party manufacturing vendor's FDA compliance, creating undisclosed delay risk for the OLC regulatory approval.\n\nThe release itself is attorney advertising with a November 2, 2026 lead plaintiff deadline; the substantive risk for holders is the alleged unresolved FDA manufacturing deficiencies rather than the litigation filing per se.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Suppress solicitation, but monitor the underlying FDA/CMC approval-delay risk for UNCY's OLC."},"keyFigures":{},"quotedText":"the regulatory approval of OLC was reasonably likely to be delayed","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky"},{"name":"Ed Korsinsky, Esq.","role":"attorney, Levi & Korsinsky"}],"products":["OLC"],"companies":[{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","relationship":"defendant / lawsuit target"},{"name":"U.S. Food and Drug Administration","relationship":"regulator cited in complaint"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"A securities class action has actually been filed against Unicycive, but this release is a Levi & Korsinsky plaintiff solicitation, not an issuer disclosure. No certified class or settlement is announced, though the underlying fraud allegations (CMC vendor deficiencies threatening OLC approval) carry real substantive risk."},"tickerRelevance":{"others":[],"primary":"UNCY"},"globalImportance":18,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"securities-class-action-filing","issuerAuthored":false,"substantiveRiskNote":"underlying FDA/CMC allegations may warrant separate tracking"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Levi & Korsinsky announced a securities fraud class action filed against Unicycive Therapeutics covering investors who purchased UNCY securities between December 29, 2025 and June 29, 2026.\n\nThe complaint alleges the company misled investors about its third-party manufacturing vendor's FDA compliance, creating undisclosed delay risk for the OLC regulatory approval.\n\nThe release itself is attorney advertising with a November 2, 2026 lead plaintiff deadline; the substantive risk for holders is the alleged unresolved FDA manufacturing deficiencies rather than the litigation filing per se.","key_figures":{},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky"},{"name":"Ed Korsinsky, Esq.","role":"attorney, Levi & Korsinsky"}],"products":["OLC"],"companies":[{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","relationship":"defendant / lawsuit target"},{"name":"U.S. Food and Drug Administration","relationship":"regulator cited in complaint"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-18T16:20:05.467Z","global_importance":18,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"securities-class-action-filing","issuerAuthored":false,"substantiveRiskNote":"underlying FDA/CMC allegations may warrant separate tracking"}},"durationMs":5028,"modelName":"glm-5.3-flashx"}}